Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma

被引：0
|
作者：
Shee, Chai Chee
Kin, Liam Chong
Kek, Pang Yong
Siong, Kow Keng
Ern, Poh Mau
Kuan, Wong Chee
Liang, Tan Jiunn
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Lung cancer / Oncology; Thoracic oncology; Molecular pathology;
D O I：
10.1183/13993003.congress-2016.OA3341
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
OA3341
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
    Chai, C. S.
    Liam, C. K.
    Lin, O. Po
    Pang, Y. K.
    Ho, G. F.
    Alip, A.
    Wong, C. K.
    Poh, M. E.
    Tan, J. L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] Combination of Chemotherapy and Gefitinib as First-Line Treatment of Patients with Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations
    Jin, Bo
    Niu, Yanjie
    Zhang, Yanwei
    Chu, Tianqing
    Gu, Aiqin
    Pei, Jun
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646
  • [3] Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
    Koehler, Jens
    Schuler, Martin
    [J]. ONKOLOGIE, 2013, 36 (09): : 510 - 518
  • [4] Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
    Copeman, Michael
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2008, 27 (1)
  • [5] Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
    Michael Copeman
    [J]. Journal of Experimental & Clinical Cancer Research, 27
  • [6] Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
    Yang, James Chih-Hsin
    Gadgeel, Shirish M.
    Sequist, Lecia VanDam
    Wu, Chien-Liang
    Papadimitrakopoulou, Vassiliki A.
    Su, Wu-Chou
    Fiore, Joseph
    Saraf, Sanatan
    Raftopoulos, Harry
    Patnaik, Amita
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : 553 - 559
  • [7] Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial
    Han, B.
    Jin, B.
    Zhang, Y.
    Chu, T.
    Gu, A.
    Xu, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S113 - S114
  • [8] Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
    Han, Baohui
    Jin, Bo
    Chu, Tianqing
    Niu, Yanjie
    Dong, Yu
    Xu, Jianlin
    Gu, Aiqing
    Zhong, Hua
    Wang, Huimin
    Zhang, Xueyan
    Shi, Chunlei
    Zhang, Yanwei
    Zhang, Wei
    Lou, Yuqing
    Zhu, Lei
    Pei, Jun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (06) : 1249 - 1256
  • [9] MOLECULAR HETEROGENEITY AND RESPONSE TO GEFITINIB OF EGFR MUTANT ADVANCED LUNG ADENOCARCINOMA
    Bria, E.
    Pilotto, S.
    Amato, E.
    Fassan, M.
    Novello, S.
    Vavala, T.
    Righi, L.
    Sperduti, I.
    Scarpa, A.
    Tortora, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S38 - S39
  • [10] PEMETREXED VERSUS GEMCITABINE IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE TREATMENT OF ADVANCED LUNG ADENOCARCINOMA
    Shee, C. Chee
    Liam, C. K.
    Pang, Y. K.
    Kow, K. S.
    Wong, C. K.
    Poh, M. E.
    Tan, J. L.
    [J]. RESPIROLOGY, 2016, 21 : 111 - 111
12345